Randomized trials of XXXX for @entity791 -associated @entity448 and @entity3085 .

@entity1 @entity137 @entity353 @entity5 @entity448 @entity3085 @entity1017 @entity6303 @entity791
Involuntary @entity353 is a frequent complication of @entity791 ( @entity791 ) and ultimately affects the majority of @entity1 . The deleterious effects of @entity353 on immune function and the physical and psychological sequelae of severe @entity353 are well recognized. @entity6303 induces appetite stimulation and nonfluid @entity1017 in @entity1 with @entity5 . In a pilot study, @entity6303 produced nonfluid @entity1017 in @entity1 with @entity791 . Two double-blind randomized placebo-controlled trials of @entity6303 for the treatment of @entity791 -related @entity448 and @entity3085 have shown improvements in body weight with treatment. In a multicenter trial reported by Flynn et al. at the 7th International Conference on @entity791 (1992), 65 @entity1 with @entity791 and @entity353 of > 10% of ideal body weight were randomized to placebo or @entity6303 800 mg/day. @entity6303 -treated @entity1 had a significantly greater mean maximum @entity1017 (p = 0.027) and appetite stimulation (p = 0.021) than did placebo-treated @entity1 . In a second, larger randomized placebo-controlled trial, 271 @entity1 with @entity791 , @entity448 and @entity3085 were randomized to receive placebo or multiple doses of @entity6303 at 100, 400 or 800 mg/day for 12 weeks. A maximum @entity1017 of at least 5 lb (2.25 kg) was observed in 64.2% of @entity1 in the 800-mg @entity6303 group compared with 21.4% in the placebo group (p < 0.0001). Mean maximum weight change from baseline to last evaluation was +8.3 lb in the 800-mg group and -1.1 lb in the placebo group (p < 0.001). Mean change in lean body mass from baseline to last evaluation was +2.5 lb in the 800-mg group versus -1.7 lb in the placebo group (p < 0.001). A significant improvement in appetite was seen in @entity1 receiving 800 mg @entity6303 compared with @entity1 receiving placebo. No significant @entity137 was observed with @entity6303 therapy. @entity6303 is an effective treatment for some @entity1 with @entity791 -related @entity448 and @entity3085 .
